Chemotherapy for malignant mesothelioma: From doxorubicin to vinorelbine

被引:33
作者
Baas, P [1 ]
机构
[1] Netherlands Canc Inst, Dept Thorac Oncol, NL-1066 CX Amsterdam, Netherlands
关键词
D O I
10.1053/sonc.2002.30231
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It has been a challenge to find effective chemotherapeutic treatments for malignant mesothelioma. Over the last several decades numerous single-drug and combination regimens have been examined, but no standard treatment with chemotherapy alone has emerged. Possible explanations for this lack of success are the heterogeneity between the different subclasses of mesothelioma and the difficulties experienced in determining responses on computed tomographic (CT) scan. This review will present the results of most chemotherapy trials. An attempt is also been made to overcome the problem of identifying the overall response rate by presenting the median survival time. Other types of response evaluation and guidelines for patient selection are warranted to properly compare chemotherapeutic treatments. Copyright © 2002 by W.B. Saunders Company.
引用
收藏
页码:62 / 69
页数:8
相关论文
共 101 条
[1]  
ADAMS VI, 1986, CANCER, V58, P1540, DOI 10.1002/1097-0142(19861001)58:7<1540::AID-CNCR2820580727>3.0.CO
[2]  
2-5
[3]   MALIGNANT PLEURAL MESOTHELIOMA - PHASE-II PILOT-STUDY OF IFOSFAMIDE AND MESNA [J].
ALBERTS, AS ;
FALKSON, G ;
VANZYL, L .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1988, 80 (09) :698-699
[4]   Ifosfamide in malignant mesothelioma:: a phase II study [J].
Andersen, MK ;
Krarup-Hansen, A ;
Mårtensson, G ;
Winther-Nielsen, H ;
Thylen, A ;
Damgaard, K ;
Olling, S ;
Wallin, J .
LUNG CANCER, 1999, 24 (01) :39-43
[5]  
ARDIZZONI A, 1991, CANCER, V67, P2984, DOI 10.1002/1097-0142(19910615)67:12<2984::AID-CNCR2820671208>3.0.CO
[6]  
2-Q
[7]   Caelyx™ in malignant mesothelioma:: A phase II EORTC study [J].
Baas, P ;
van Meerbeeck, J ;
Groen, H ;
Schouwink, H ;
Burgers, S ;
Daamen, S ;
Giaccone, G .
ANNALS OF ONCOLOGY, 2000, 11 (06) :697-700
[8]  
BAJORIN D, 1987, CANCER TREAT REP, V71, P857
[9]  
BELANI CP, 1999, P AN M AM SOC CLIN, V18, pA1829
[10]  
Bénard F, 1999, J NUCL MED, V40, P1241